bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 4b from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 4b. A serial section shows the same microscopic field after processing for PTEN localization by immunohistochemistry. Note the lack of immunostaining in the tumor cells.
Supplemental Figure 4a from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 4a. PTEN IHC assay validation and QD-FISH. A. Hematoxylin-and-eosin stained section of human prostate shows a focus of early prostatic adenocarcinoma.
Supplementary Figures from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection
Authors: Wu Ting-Jung , Chang Shih-Shin , Li Chia-Wei , Hsu Yi-Hsin , Chen Tse-Ching , Lee Wei-Chen , Yeh Chau-Ting , Hung Mien-Chie
Published: April 2023

Supplementary Figure S1. Immunoblot and heatmap of EMT regulators in HCC. Supplementary Figure S2. immunofluorescence, immunoblot, and cell counting of HCC cells with or without Snail knockdown. Supplementary Figure S3. Identification of TNF-α mediated Snail up-regulation through canonical NF-κB activation. Supplementary Figure S4. The effect of TNF α on Snail expression in MEFs Supplementary Figure S5. The effect of TNFa and NF-kB inhibitor on Snail in various HCC cell lines. Supplementary Figure S6. TNF-α-mediated NF-κB activation and EMT in HCC cells through RelA (p65) nuclear translocation.
Supplemental Figure 2 from PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
Authors: Stern Howard M. , Gardner Humphrey , Burzykowski Tomasz , Elatre Wafaa , O'Brien Carol , Lackner Mark R. , Pestano Gary A. , Santiago Angela , Villalobos Ivonne , Eiermann Wolfgang , Pienkowski Tadeusz , Martin Miguel , Robert Nicholas , Crown John , Nuciforo Paolo , Bee Valerie , Mackey John , Slamon Dennis J. , Press Michael F.
Published: April 2023

Supplemental Figure 2. Clinical outcome based on PTEN data availability. Kaplan Meier analysis was performed for patients with PTEN data available compared to patients without PTEN data available. Disease free survival (A, C) and overall survival (B, D) are shown for BCIRG 006 (HER2-amplified) (A, B) and BCIRG 005 (HER2-non-amplified) (C, D).
Supplementary figure 4 from Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer
Authors: Banerjee Sulagna , Modi Shrey , McGinn Olivia , Zhao Xianda , Dudeja Vikas , Ramakrishnan Sundaram , Saluja Ashok K.
Published: April 2023

Expression and activity of HA synthesis and degradation genes
Supplemental Figure 1 from A Supplemented High-Fat Low-Carbohydrate Diet for the Treatment of Glioblastoma
Authors: Martuscello Regina T. , Vedam-Mai Vinata , McCarthy David J. , Schmoll Michael E. , Jundi Musa A. , Louviere Christopher D. , Griffith Benjamin G. , Skinner Colby L. , Suslov Oleg , Deleyrolle Loic P. , Reynolds Brent A.
Published: April 2023

Glucose restriction slows proliferation of multiple patient-derived glioblastoma stem cell lines.
Supplementary figure 2 from Impaired Synthesis of Stromal Components in Response to Minnelide Improves Vascular Function, Drug Delivery, and Survival in Pancreatic Cancer
Authors: Banerjee Sulagna , Modi Shrey , McGinn Olivia , Zhao Xianda , Dudeja Vikas , Ramakrishnan Sundaram , Saluja Ashok K.
Published: April 2023

Quantitation of area stained in immunohistochenistry
Supplemental Table 4 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
Authors: Boyiadzis Michael , Arora Mukta , Klein John P. , Hassebroek Anna , Hemmer Michael , Urbano-Ispizua Alvaro , Antin Joseph H. , Bolwell Brian J. , Cahn Jean-Yves Y. , Cairo Mitchell S. , Cutler Corey S. , Flowers Mary E. , Gale Robert P. , Herzig Roger , Isola Luis M. , Jacobsohn David A. , Jagasia Madan H. , Klumpp Thomas R. , Lee Stephanie J. , Petersdorf Effie W. , Santarone Stella , Spellman Stephen R. , Schouten Harry C. , Verdonck Leo F. , Wingard John R. , Weisdorf Daniel J. , Horowitz Mary M. , Pavletic Steven Z.
Published: April 2023

Supplemental Table 4. Multivariate analysis showing impact of cGVHD characteristics on treatment related mortality, disease free survival, overall survival in patients with AML, ALL, MDS who developed cGVHD
Supplemental Table 1 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
Authors: Boyiadzis Michael , Arora Mukta , Klein John P. , Hassebroek Anna , Hemmer Michael , Urbano-Ispizua Alvaro , Antin Joseph H. , Bolwell Brian J. , Cahn Jean-Yves Y. , Cairo Mitchell S. , Cutler Corey S. , Flowers Mary E. , Gale Robert P. , Herzig Roger , Isola Luis M. , Jacobsohn David A. , Jagasia Madan H. , Klumpp Thomas R. , Lee Stephanie J. , Petersdorf Effie W. , Santarone Stella , Spellman Stephen R. , Schouten Harry C. , Verdonck Leo F. , Wingard John R. , Weisdorf Daniel J. , Horowitz Mary M. , Pavletic Steven Z.
Published: April 2023

Supplemental Table 1. Multivariate analysis of late relapse, transplant-related mortality, overall survival after HCT for each disease (AML, ALL, CML, MDS)
Supplementary Figure 5 from Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Authors: Ziemke Elizabeth K. , Dosch Joseph S. , Maust Joel D. , Shettigar Amrith , Sen Ananda , Welling Theodore H. , Hardiman Karin M. , Sebolt-Leopold Judith S.
Published: April 2023

Treatment-related Weight Loss in CRC PDX Models Treated with a Combination of Trametinib and Palbociclib. Graphical representation of body weight loss in five CRC PDX models confirming that combination therapy was well tolerated.
Supplemental Table 7-10 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Authors: Beuselinck Benoit , Job Sylvie , Becht Etienne , Karadimou Alexandra , Verkarre Virginie , Couchy Gabrielle , Giraldo Nicolas , Rioux-Leclercq Nathalie , Molinié Vincent , Sibony Mathilde , Elaidi Reza , Teghom Corinne , Patard Jean-Jacques , Méjean Arnaud , Fridman Wolf Herman , Sautès-Fridman Catherine , de Reyniès Aurélien , Oudard Stéphane , Zucman-Rossi Jessica
Published: April 2023

Supplemental Table 7-10. Table S7: Area under the ROC curve or c-index for the predictive and prognostic markers presented in Table 1 and Figures 3A, 3B and 3C. Table S8: P-values of the pathway enrichment analysis for the genes differentially expressed, the genes differentially methylated and the genes differentially methylated and anti-correlated to expression data in the four unsupervised subgroups. Table S9: List of the recurrent chromosomal aberrations characterizing ccrcc4-samples with a sensitivity and a specificity greater than 0.65. Table S10: Correlation of the centroids of our classification in four subtypes with the Brannon classification in three subgroups ccA, ccB and cluster_3 and the subtypes predicted in the TCGA cohort
Supplemental Figure 1-3 from Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
Authors: Beuselinck Benoit , Job Sylvie , Becht Etienne , Karadimou Alexandra , Verkarre Virginie , Couchy Gabrielle , Giraldo Nicolas , Rioux-Leclercq Nathalie , Molinié Vincent , Sibony Mathilde , Elaidi Reza , Teghom Corinne , Patard Jean-Jacques , Méjean Arnaud , Fridman Wolf Herman , Sautès-Fridman Catherine , de Reyniès Aurélien , Oudard Stéphane , Zucman-Rossi Jessica
Published: April 2023

Supplemental Figure 1-3. Figure S1: Expression of immune modulators among the 4 molecular subgroups and normal Samples; Figure S2: Expression of cell-type specific metagenes among the different subgroups and normal samples; Figure S3: CD8+ cell infiltration according to the molecular ccRCC subtype classification.
Supplementary Table 5 from MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis
Authors: Tong Joanna H. , Yeung Sai F. , Chan Anthony W.H. , Chung Lau Y. , Chau Shuk L. , Lung Raymond Wai Ming , Tong Carol Y. , Chow Chit , Tin Edith K.Y. , Yu Yau H. , Li Hui , Pan Yi , Chak Wing P. , Ng Calvin S.H. , Mok Tony S.K. , To Ka F.
Published: April 2023

Correlation between MET IHC and DNA alterations in NSCLC samples
Supplementary Table 4 from MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis
Authors: Tong Joanna H. , Yeung Sai F. , Chan Anthony W.H. , Chung Lau Y. , Chau Shuk L. , Lung Raymond Wai Ming , Tong Carol Y. , Chow Chit , Tin Edith K.Y. , Yu Yau H. , Li Hui , Pan Yi , Chak Wing P. , Ng Calvin S.H. , Mok Tony S.K. , To Ka F.
Published: April 2023

Summary of 29 MET FISH positive NSCLC and their co-mutation status
Supplementary Table 1 from MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis
Authors: Tong Joanna H. , Yeung Sai F. , Chan Anthony W.H. , Chung Lau Y. , Chau Shuk L. , Lung Raymond Wai Ming , Tong Carol Y. , Chow Chit , Tin Edith K.Y. , Yu Yau H. , Li Hui , Pan Yi , Chak Wing P. , Ng Calvin S.H. , Mok Tony S.K. , To Ka F.
Published: April 2023

Clinicopathologic characteristics of the study cohort
Supplementary Figure 2 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Authors: O'Shaughnessy Joyce , Koeppen Hartmut , Xiao Yuanyuan , Lackner Mark R. , Paul Devchand , Stokoe Christopher , Pippen John , Krekow Lea , Holmes Frankie Ann , Vukelja Svetislava , Lindquist Deborah , Sedlacek Scot , Rivera Ragene , Brooks Robert , McIntyre Kristi , Brownstein Carrie , Hoersch Silke , Blum Joanne L. , Jones Stephen
Published: April 2023

Figure S2: Distribution of central Ki-67 scores in (A) ER-positive/HER2-negative breast cancer (n=824) and (B) TNBC (n=454)
Supplementary Figure 1 from Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Authors: O'Shaughnessy Joyce , Koeppen Hartmut , Xiao Yuanyuan , Lackner Mark R. , Paul Devchand , Stokoe Christopher , Pippen John , Krekow Lea , Holmes Frankie Ann , Vukelja Svetislava , Lindquist Deborah , Sedlacek Scot , Rivera Ragene , Brooks Robert , McIntyre Kristi , Brownstein Carrie , Hoersch Silke , Blum Joanne L. , Jones Stephen
Published: April 2023

Figure S1: Forest plot of hazard ratios by subgroup in the ITT population (planned analysis) for (A) DFS and (B) OS
Supplementary Figure 7 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

c-Myc indicates the therapeutic response to FGFR inhibition in vivo.
Supplementary Table S1 and S2 from Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
Authors: Ory Benjamin , Baud'huin Marc , Verrecchia Franck , Royer Bénédicte Brounais-Le , Quillard Thibaut , Amiaud Jérôme , Battaglia Séverine , Heymann Dominique , Redini Francoise , Lamoureux Francois
Published: April 2023

Primer and antibodies table
Supplemental Figure 3 from Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression
Authors: Ory Benjamin , Baud'huin Marc , Verrecchia Franck , Royer Bénédicte Brounais-Le , Quillard Thibaut , Amiaud Jérôme , Battaglia Séverine , Heymann Dominique , Redini Francoise , Lamoureux Francois
Published: April 2023

Supp. Figure 3. Tumors were collected after 42 days and HSP70, MET; FAK and MMP9 were evaluated by immunohistochemical analysis. Specimens were scored and estimated in percentage of positive cells.
Supplementary Figure 3 from c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Authors: Liu Hongyan , Ai Jing , Shen Aijun , Chen Yi , Wang Xinyi , Peng Xia , Chen Hui , Shen Yanyan , Huang Min , Ding Jian , Geng Meiyu
Published: April 2023

c-Myc downregulation determines the response to FGFR3 inhibition in FGFR3-addicted cancer cells.
Supplementary Table 2 from Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Authors: Bellini Angela , Bernard Virginie , Leroy Quentin , Rio Frio Thomas , Pierron Gaelle , Combaret Valérie , Lapouble Eve , Clement Nathalie , Rubie Herve , Thebaud Estelle , Chastagner Pascal , Defachelles Anne Sophie , Bergeron Christophe , Buchbinder Nimrod , Taque Sophie , Auvrignon Anne , Valteau-Couanet Dominique , Michon Jean , Janoueix-Lerosey Isabelle , Delattre Olivier , Schleiermacher Gudrun
Published: April 2023

Supplementary Table 2. Primer sequences used for the amplification of ALK regions of interested in the first PCR-step
Supplemental Tables S1-2 and Figures S1-2 from NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma
Authors: Cescon David W. , She Desmond , Sakashita Shingo , Zhu Chang-Qi , Pintilie Melania , Shepherd Frances A. , Tsao Ming-Sound
Published: April 2023

Supplemental Tables S1-2 and Figures S1-2. Table S1 - primers used for sequencing of NRF2 and KEAP1; Table S2 - Lists of differentially expressed genes comprising NRF2ACT signature; Figure S1- Distribution of NRF2 and KEAP1 IHC H-scores; Figure S2 - Clustering of adenocarcinoma subset of UHN181 dataset using NRF2ACT.
supplemental material-Figure S3 from Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer
Authors: Guo Xingjun , Zheng Lei , Jiang Jianxin , Zhao Yan , Wang Xin , Shen Ming , Zhu Feng , Tian Rui , Shi Chengjian , Xu Meng , Li Xu , Peng Feng , Zhang Hang , Feng Yechen , Xie Yu , Xu Xiaodong , Jia Wei , He Ruizhi , Xie Chencheng , Hu Jun , Ye Dawei , Wang Min , Qin Renyi
Published: April 2023

Figure S3: IL-18 promotes PC cell proliferation.
Supplementary Figure Legends from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 6 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Figure 6. Analysis of SNP6.0 arrays of GBM harboring CNVs of FGFR3 and TACC3 genomic loci.
Supplementary Figure 1 from Detection, Characterization, and Inhibition of FGFR–TACC Fusions in IDH Wild-type Glioma
Authors: Di Stefano Anna Luisa , Fucci Alessandra , Frattini Veronique , Labussiere Marianne , Mokhtari Karima , Zoppoli Pietro , Marie Yannick , Bruno Aurelie , Boisselier Blandine , Giry Marine , Savatovsky Julien , Touat Mehdi , Belaid Hayat , Kamoun Aurelie , Idbaih Ahmed , Houillier Caroline , Luo Feng R. , Soria Jean-Charles , Tabernero Josep , Eoli Marica , Paterra Rosina , Yip Stephen , Petrecca Kevin , Chan Jennifer A. , Finocchiaro Gaetano , Lasorella Anna , Sanson Marc , Iavarone Antonio
Published: April 2023

Supplementary Figure 1. Genomic PCR images and Sanger sequences of FGFR3-TACC3 genomic breakpoints.
Supplementary figure 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Authors: van Gool Inge C. , Eggink Florine A. , Freeman-Mills Luke , Stelloo Ellen , Marchi Emanuele , de Bruyn Marco , Palles Claire , Nout Remi A. , de Kroon Cor D. , Osse Elisabeth M. , Klenerman Paul , Creutzberg Carien L. , Tomlinson Ian P.M. , Smit Vincent T.H.B.M. , Nijman Hans W. , Bosse Tjalling , Church David N.
Published: April 2023

Supplementary figure 1. Tumor infiltrating lymphocytes and Crohn's like reaction in POLE- mutant endometrioid endometrial cancers
Supplementary Table 1 from Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients
Authors: Mayerhoefer Marius E. , Karanikas Georgios , Kletter Kurt , Prosch Helmut , Kiesewetter Barbara , Skrabs Cathrin , Porpaczy Edit , Weber Michael , Knogler Thomas , Sillaber Christian , Jaeger Ulrich , Simonitsch-Klupp Ingrid , Ubl Philipp , Müllauer Leonhard , Dolak Werner , Lukas Julius , Raderer Markus
Published: April 2023

Supplementary Table 1. Histologic data, therapy schemes, and follow-up (FU) results according to 18F-FDG-PET/CT
Supplementary Materials from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
Authors: van Poelgeest Mariëtte I.E. , Welters Marij J.P. , Vermeij Renee , Stynenbosch Linda F.M. , Loof Nikki M. , Berends-van der Meer Dorien M.A. , Löwik Margriet J.G. , Hamming Ineke L.E. , van Esch Edith M.G. , Hellebrekers Bart W.J. , van Beurden Marc , Schreuder Henk W. , Kagie Marjolein J. , Trimbos J. Baptist M.Z. , Fathers Lorraine M. , Daemen Toos , Hollema Harry , Valentijn A. Rob P.M. , Oostendorp Jaap , Oude Elberink J. Hanneke N.G. , Fleuren Gertjan J. , Bosse Tjalling , Kenter Gemma G. , Stijnen Theo , Nijman Hans W. , Melief Cornelis J.M. , van der Burg Sjoerd H.
Published: April 2023

supplementary material and methods Table S1. Reasons for exclusion of patients from outcome analysis Table S2. Summary statistics of patient groups according to linear mixed model analysis Table S3. All related systemic adverse events by study group Table S4. Swelling size of injection site at 12 months follow-up (safety population) Table S5. Overview of treatment-related severe adverse events in patients who received at least one ISA101 vaccination with or without imiquimod Table S6. Overview of serious adverse events (safety population) Figure S1. Study Profile Figure S2. Example of detection of HPV16-specific CD8+ T-cell response measured by flow cytometry Figure S3. Example of detection of HPV16-specific CD8+ T-cell response measured by ex-vivo CD8+ T-cell IFNÎ³-ELISPOT Figure S4. HPV16-specific CD8+ T-cell reactivity of the PP population Figure S5. No differences in immune response to recall antigens upon treatment Figure S6. Strength of the HPV16-specific immunity versus clinical measurements at 12 months follow-up The strength of the immune response prior to vaccination (pre), after 2 vaccinations (2) and after 4 vaccinations (4) is depicted when ITT patients were grouped according to presence (open circle) or absence (closed circle) of VIN lesion (histology), HPV16 DNA (virology),a non-CR (NR/PR; open circles) or CR (closed circles) at 12 months after the last vaccination. Figure S7. Strength of the HPV16-specific immune responses in the PP population Figure S8. Granulomatous dermatitis at ISA101 vaccination site Figure S9. Basophil activation assay
Supplementary Table S3 from LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival
Authors: Torres Sofía , Garcia-Palmero Irene , Herrera Mercedes , Bartolomé Rubén A. , Peña Cristina , Fernandez-Aceñero M. Jesús , Padilla Guillermo , Peláez-García Alberto , Lopez-Lucendo María , Rodriguez-Merlo Rufo , de Herreros Antonio García , Bonilla Félix , Casal J. Ignacio
Published: April 2023

Supplementary Table S3. List of proteins differentially-expressed in the whole cellular extract and conditioned medium of CAFs with a fold-change >1.5
Supplementary Figure S2B from Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Authors: Janni Wolfgang J. , Rack Brigitte , Terstappen Leon W.M.M. , Pierga Jean-Yves , Taran Florin-Andrei , Fehm Tanja , Hall Carolyn , de Groot Marco R. , Bidard François-Clement , Friedl Thomas W.P. , Fasching Peter A. , Brucker Sara Y. , Pantel Klaus , Lucci Anthony
Published: April 2023

Figure S2. Hazard ratios (black line) and 95% confidence intervals (blue area) from the univariate survival analyses according to the presence of CTCs categorized using different cutoff values (e.g., cutoff 0: 0 CTCs vs. > 0; cutoff 1: 0-1 CTCs vs. > 1; cutoff 2: 0-2 CTCs vs. > 2). Panel A shows breast-cancer-specific survival, and Panel B shows distant disease-free survival.
Supplementary Table S3 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
Authors: Ekmekcioglu Suhendan , Davies Michael A. , Tanese Keiji , Roszik Jason , Shin-Sim Myung , Bassett Roland L. , Milton Denái R. , Woodman Scott E. , Prieto Victor G. , Gershenwald Jeffrey E. , Morton Donald L. , Hoon Dave S. , Grimm Elizabeth A.
Published: April 2023

This file contains adjuvant treatment distribution in validation set (MDACC) in all patients.
Supplementary Material S2 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
Authors: Ekmekcioglu Suhendan , Davies Michael A. , Tanese Keiji , Roszik Jason , Shin-Sim Myung , Bassett Roland L. , Milton Denái R. , Woodman Scott E. , Prieto Victor G. , Gershenwald Jeffrey E. , Morton Donald L. , Hoon Dave S. , Grimm Elizabeth A.
Published: April 2023

Overview of the strategy used for the discovery and validation of inflammatory protein signature. Flow of samples for analyses in both datasets presented here.
Supplemantary Figure S1 from Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
Authors: Ekmekcioglu Suhendan , Davies Michael A. , Tanese Keiji , Roszik Jason , Shin-Sim Myung , Bassett Roland L. , Milton Denái R. , Woodman Scott E. , Prieto Victor G. , Gershenwald Jeffrey E. , Morton Donald L. , Hoon Dave S. , Grimm Elizabeth A.
Published: April 2023

Univariate analyses of survival models with individual markers in discovery and validation sets. Forest plots of OS and RFS hazard ratios and associated 95% confidence intervals for specific protein expression from univariate Cox proportional hazards regression models presented as percentage in each group in discovery (A) and validation (B) datasets.
Supplementary Table 1 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

Incidence of treatment-emergent adverse events, all grades, occurring in {greater than or equal to}20% of patients in either cohort
Supplementary Figure 1 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
Authors: Adjei Alex A. , Richards Donald A. , El-Khoueiry Anthony , Braiteh Fadi , Becerra Carlos H.R. , Stephenson Joe J. , Hezel Aram F. , Sherman Morris , Garbo Lawrence , Leffingwell Diane P. , Iverson Cory , Miner Jeffrey N. , Shen Zancong , Yeh Li-Tain , Gunawan Sonny , Wilson David M. , Manhard Kimberly J. , Rajagopalan Prabhu , Krissel Heiko , Clendeninn Neil J.
Published: April 2023

pERK levels in hair follicles by dose level and course
Conflict of Interest Form from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Authors: Niemann Carsten U. , Herman Sarah E.M. , Maric Irina , Gomez-Rodriguez Julio , Biancotto Angelique , Chang Betty Y. , Martyr Sabrina , Stetler-Stevenson Maryalice , Yuan Constance M. , Calvo Katherine R. , Braylan Raul C. , Valdez Janet , Lee Yuh Shan , Wong Deanna H. , Jones Jade , Sun Clare , Marti Gerald E. , Farooqui Mohammed Z.H. , Wiestner Adrian
Published: April 2023

Conflict of Interest Form from Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study
Supplementary Materials and Methods from Identification and Functional Validation of Reciprocal microRNA–mRNA Pairings in African American Prostate Cancer Disparities
Authors: Wang Bi-Dar , Ceniccola Kristin , Yang Qi , Andrawis Ramez , Patel Vyomesh , Ji Youngmi , Rhim Johng , Olender Jacqueline , Popratiloff Anastas , Latham Patricia , Lai Yinglei , Patierno Steven R. , Lee Norman H.
Published: April 2023

Supplementary Materials and Methods. Detailed information of the clinical samples, IHC procedure, pathway analysis, PCa cell lines and functional assays used in the study.
Supplemental Table S3 from An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors
Authors: Tobin Nicholas P. , Wennmalm Kristian , Lindström Linda S. , Foukakis Theodoros , He Liqun , Genové Guillem , Östman Arne , Landberg Göran , Betsholtz Christer , Bergh Jonas
Published: April 2023

Multivariable analysis of prognostic markers in endocrine-treated patients
Supplementary Figures 10-11 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Supplementary Figure 10 - Additional measurements of PlGF and VEGF-B; Supplementary Figure 11 - Additional effects of PlGF deletion on obesity-induced tumor progression and systemic metabolism.
Supplementary Table 6 from Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis
Authors: Crona Joakim , Backman Samuel , Maharjan Rajani , Mayrhofer Markus , Stålberg Peter , Isaksson Anders , Hellman Per , Björklund Peyman
Published: April 2023

Supplementary Table 6. Clinical parameters of the included patients
Supplementary Figure 6 from PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity
Authors: Incio Joao , Tam Josh , Rahbari Nuh N. , Suboj Priya , McManus Dan T. , Chin Shan M. , Vardam Trupti D. , Batista Ana , Babykutty Suboj , Jung Keehoon , Khachatryan Anna , Hato Tai , Ligibel Jennifer A. , Krop Ian E. , Puchner Stefan B. , Schlett Christopher L. , Hoffmman Udo , Ancukiewicz Marek , Shibuya Masabumi , Carmeliet Peter , Soares Raquel , Duda Dan G. , Jain Rakesh K. , Fukumura Dai
Published: April 2023

Effects of VEGFR-1 signaling ablation on glucose/insulin tolerance and insulin production by the pancreas during obesity.
Supplementary Figure 7 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Phenotypic analyses of PECs depleted with CD8+ T cells
Supplementary Figure 7 from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Figure S7. Knockdown of NDUFA4L2 suppresses tumor growth and reduces cell migratory ability.
Supplementary Figure 2 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Authors: Ma Zhifeng , Li Wen , Yoshiya Shinichi , Xu Yunfeng , Hata Masaki , El-Darawish Yosif , Markova Tzvetanka , Yamanishi Kyosuke , Yamanishi Hiromichi , Tahara Hideaki , Tanaka Yoshimasa , Okamura Haruki
Published: April 2023

Phenotypic analyses of NK cells and T cells in PECs derived from CT-26 pre-implanted mice receiving immune checkpoint blocking mAbs and IL-18
Supplementary Figure 3 from NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma
Authors: Lai Robin Kit-Ho , Xu Iris Ming-Jing , Chiu David Kung-Chun , Tse Aki Pui-Wah , Wei Larry Lai , Law Cheuk-Ting , Lee Derek , Wong Chun-Ming , Wong Maria Pik , Ng Irene Oi-Lin , Wong Carmen Chak-Lui
Published: April 2023

Figure S3. HIF-1α positively regulates NDUFA4L2 in hypoxia.
Supplemental Table 4 from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Table 4. Clinical characteristics of patients prior to surgery and PDX establishment
Supplementary Figure S3 from Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Authors: Arena Sabrina , Bellosillo Beatriz , Siravegna Giulia , Martínez Alejandro , Cañadas Israel , Lazzari Luca , Ferruz Noelia , Russo Mariangela , Misale Sandra , González Iria , Iglesias Mar , Gavilan Elena , Corti Giorgio , Hobor Sebastijan , Crisafulli Giovanni , Salido Marta , Sánchez Juan , Dalmases Alba , Bellmunt Joaquim , De Fabritiis Gianni , Rovira Ana , Di Nicolantonio Federica , Albanell Joan , Bardelli Alberto , Montagut Clara
Published: April 2023

Supplementary Figure S3. Nucleotide sequence of the EGFR gene in cetuximab resistant cell lines.
Supplemental Table 1 from AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma
Authors: Brand Toni M. , Iida Mari , Stein Andrew P. , Corrigan Kelsey L. , Braverman Cara M. , Coan John P. , Pearson Hannah E. , Bahrar Harsh , Fowler Tyler L. , Bednarz Bryan P. , Saha Sandeep , Yang David , Gill Parkash S. , Lingen Mark W. , Saloura Vassiliki , Villaflor Victoria M. , Salgia Ravi , Kimple Randall J. , Wheeler Deric L.
Published: April 2023

Supplemental Table 1. Clinical information describing HNSCC cohort
Supplementary Tables from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Authors: Mangsbo Sara M. , Broos Sissela , Fletcher Erika , Veitonmäki Niina , Furebring Christina , Dahlén Eva , Norlén Per , Lindstedt Malin , Tötterman Thomas H. , Ellmark Peter
Published: April 2023

Supplementary Table 1. Selection strategy Supplementary Table 2. Kinetic parameters for ADC-1013 and B44 measured by Biacore Supplementary Table 3. In vitro potency (EC50) of ADC-1013 in DC and B cell assays Supplementary table 4. Phenotypic profiling of hCD40tg mice
Supplementary Figure 6 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Authors: Mangsbo Sara M. , Broos Sissela , Fletcher Erika , Veitonmäki Niina , Furebring Christina , Dahlén Eva , Norlén Per , Lindstedt Malin , Tötterman Thomas H. , Ellmark Peter
Published: April 2023

Supplementary Figure 6. Splenocytes from complete responders (CR) from ADC-1013 treatment of MB40 tumors were transplanted to naive mice. The receiving naïve mice were then challenged with MB49 tumors and the tumor volume followed over time until the first mice was sacrificed (**p<0.01, two-way ANOVA over time).
Supplementary Figure 2 from The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity
Authors: Mangsbo Sara M. , Broos Sissela , Fletcher Erika , Veitonmäki Niina , Furebring Christina , Dahlén Eva , Norlén Per , Lindstedt Malin , Tötterman Thomas H. , Ellmark Peter
Published: April 2023

Supplementary Figure 2. Microphotographs from cryo sections showing representative images of A) Spleen, B) Liver and C) Brain (one slide representing data from one female and one male mice) from hCD40+ mice stained with an anti-human CD40 antibody or anti mouse CD40 antibody.
Supplemental figure 2 from A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
Authors: Ko Andrew H. , Bekaii-Saab Tanios , Van Ziffle Jessica , Mirzoeva Olga M. , Joseph Nancy M. , Talasaz AmirAli , Kuhn Peter , Tempero Margaret A. , Collisson Eric A. , Kelley R. Kate , Venook Alan P. , Dito Elizabeth , Ong Anna , Ziyeh Sharvina , Courtin Ryan , Linetskaya Regina , Tahiri Sanaa , Korn W. Michael
Published: April 2023

Supplemental figure 2. Distribution of proportion of E-cadherin expressing tumor cells across all cases.
Supplementary materials and methods and figure legends from Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Authors: Kuo Peiwen , Bratman Scott V. , Shultz David B. , von Eyben Rie , Chan Cato , Wang Ziwei , Say Carmen , Gupta Aparna , Loo Bill W. , Giaccia Amato J. , Koong Albert C. , Diehn Maximilian , Le Quynh-Thu
Published: April 2023

Supplementary materials and methods and figure legends from Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Supplementary Figure 5 from Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Authors: Kuo Peiwen , Bratman Scott V. , Shultz David B. , von Eyben Rie , Chan Cato , Wang Ziwei , Say Carmen , Gupta Aparna , Loo Bill W. , Giaccia Amato J. , Koong Albert C. , Diehn Maximilian , Le Quynh-Thu
Published: April 2023

Radiation-related lymphopenia is associated with worse distant, local and regional progression free survival in NSCLC, in similar between radiation and cetuximab or cisplatin treated HNSCC and its severity trends with relapse in HNSCC. A higher rise in plasma Gal-1 was also seen with relapse.
Supplementary Movie S3 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Movie S3. A PSMA positive xenograft pre-stained with YC-27 was placed behind the peritoneum of a pig during laparoscopic surgery. The xenograft could easily be detected with the help of the LumiNIR{trade mark, serif} system and removed with the NIR guidance.
Supplementary Figure 4 from Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Authors: Kuo Peiwen , Bratman Scott V. , Shultz David B. , von Eyben Rie , Chan Cato , Wang Ziwei , Say Carmen , Gupta Aparna , Loo Bill W. , Giaccia Amato J. , Koong Albert C. , Diehn Maximilian , Le Quynh-Thu
Published: April 2023

Gal-1 inhibition increases tumor radiation response in vitro and in vivo.
Supplementary Movie S2 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Movie S2. The intensity of the signal is proportional to the power of the laser used. During the surgery we intentionally changed the intensity of the laser to observe the change in intensity of the signal from the kidney.
Supplementary Figure 2 from Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Authors: Kuo Peiwen , Bratman Scott V. , Shultz David B. , von Eyben Rie , Chan Cato , Wang Ziwei , Say Carmen , Gupta Aparna , Loo Bill W. , Giaccia Amato J. , Koong Albert C. , Diehn Maximilian , Le Quynh-Thu
Published: April 2023

Tumor irradiation effect on T lymphocytes, common lymphoid progenitor cells (CLPs) and Gal-1 expression in bone marrow cells.
Supplementary Figures S10-S12 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Figures S10-S12. S10. Comparison of the LumiNIR{trade mark, serif} System to the Da Vinci® System. S11. Detection limitation of YC-27 in ODYSSEY. S12. Detection limitation of YC-27 in PEARL®.
Supplementary Figures S1-S2 from Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
Authors: Neuman Brian P. , Eifler John B. , Castanares Mark , Chowdhury Wasim H. , Chen Ying , Mease Ronnie C. , Ma Rong , Mukherjee Amarnath , Lupold Shawn E. , Pomper Martin G. , Rodriguez Ronald
Published: April 2023

Supplementary Figures S1-S2. S1. Schematic of the LimiNIR{trade mark, serif} System S2. PSMA expression in mouse epididymis and RT-PCR to validate the presence of PSMA mRNA
Supplementary Material Figure legend to Figure S1 and Figure S2 from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia
Authors: Seipel Katja , Marques Miguel Teixera , Bozzini Marie-Ange , Meinken Christina , Mueller Beatrice U. , Pabst Thomas
Published: April 2023

Supplementary Material Figure legend to Figure S1 and Figure S2
Supplementary Figure S1 from Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia
Authors: Seipel Katja , Marques Miguel Teixera , Bozzini Marie-Ange , Meinken Christina , Mueller Beatrice U. , Pabst Thomas
Published: April 2023

Fig. S1 Inactivation of CEBPA, KLF4 and p53 in AML blasts and normal HSCs.
Supplemental Table S2 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental Table S2A: Analytical validation- interlaboratory precision, and Table S2B: Fitness-for-purpose clinical utility- intertumoral biological variability
Supplemental Table S1 from Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use
Authors: Srivastava Apurva K. , Jaganathan Soumya , Stephen Laurie , Hollingshead Melinda G. , Layhee Adam , Damour Eric , Govindharajulu Jeevan Prasaad , Donohue Jennifer , Esposito Dominic , Mapes James P. , Kinders Robert J. , Takebe Naoko , Tomaszewski Joseph E. , Kummar Shivaani , Doroshow James H. , Parchment Ralph E.
Published: April 2023

This file contains supplemental Table S1A: Analytical validation- sample dilution linearity, and Table S1B: Analytical validation- accuracy determined by spike recoveries
Supplementary Table 1 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

Baseline clinical and tumor pathological characteristics. Data are shown for all patients with metastatic breast cancer included in the TEX clinical trial and the subset of patients included in whole genome transcriptional analyses.
Supplementary Figure S3 from Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis–Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Authors: Kimbung Siker , Johansson Ida , Danielsson Anna , Veerla Srinivas , Egyhazi Brage Suzanne , Frostvik Stolt Marianne , Skoog Lambert , Carlsson Lena , Einbeigi Zakaria , Lidbrink Elisabet , Linderholm Barbro , Loman Niklas , Malmström Per-Olof , Söderberg Martin , Walz Thomas M. , Fernö Mårten , Hatschek Thomas , Hedenfalk Ingrid
Published: April 2023

A. Association between the 17-gene signature and IntClust subgroups. P-value is from anova test. B. Relapse free survival for the subset of patients in IntClust subgroups 3, 7 and 8, which are enriched for Luminal A tumors. 73% of tumors with high expression belonged to IntClust subgroup 3, while 41% of tumors with low expression were of subgroup 7 and 8. C. Associations between the 17 liver metastasis-selective genes and RFS and D. OS for all patients included in GOBO irrespective of ER status.
Supplementary File S1: Description of normalization methods used from Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer
Authors: Chaudhary Kumardeep , Poirion Olivier B. , Lu Liangqun , Garmire Lana X.
Published: April 2023

Description of normalization methods used
Supplementary Figures S1, S2, and S3 from Deep Learning–Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer
Authors: Chaudhary Kumardeep , Poirion Olivier B. , Lu Liangqun , Garmire Lana X.
Published: April 2023

Figures S1: Best cluster selection, S2: Comparisons of alternative methods with deep-learning based method and S3: Differential tests for miRNAs and Methylation.
Supplementary Tables 1-9 from Significant Association of Oncogene YAP1 with Poor Prognosis and Cetuximab Resistance in Colorectal Cancer Patients
Authors: Lee Keun-Wook , Lee Sung Sook , Kim Sang-Bae , Sohn Bo Hwa , Lee Hyun-Sung , Jang Hee-Jin , Park Yun-Yong , Kopetz Scott , Kim Sung Soo , Oh Sang Cheul , Lee Ju-Seog
Published: April 2023

Supplementary Tables 1-9. Supplementary Table 1. Genes in YAP1-specific expression signature. Supplementary Table 2. Clinical characteristics compared between IYCC and AYCC groups in cohort 1 (N = 229) Supplementary Table 3. Clinical characteristics compared between IYCC and AYCC groups in cohort 2 (N = 168) Supplementary Table 4. Clinical characteristics compared between IYCC and AYCC groups in cohort 3 (N = 506) Supplementary Table 5. Clinical characteristics compared between IYCC and AYCC groups in cohort 4 (N = 125) Supplementary Table 6. Clinical and genetic characteristic compared between IYCC and AYCC groups in cohort 6 Supplementary Table 7. Univariate and multivariate analyses on factors affecting DFS in stage 1-3 patients (patient data from cohorts 1 and 2; N = 3971) Supplementary Table 8. Univariate and multivariate analyses on factors affecting DFS in stage 1-3 patients (cohort 3; N = 506) Supplementary Table 9. KRAS distribution and response to cetuximab chemotherapy according to YAP1 signature in cohort 5 (N = 80)
Supplementary Figure 2 from Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
Authors: Rothenberg S. Michael , McFadden David G. , Palmer Edwin L. , Daniels Gilbert H. , Wirth Lori J.
Published: April 2023

Supplementary Figure 2. Percent radioiodine uptake by region, all patients.
Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
Authors: Ohue Yoshihiro , Kurose Koji , Mizote Yu , Matsumoto Hirofumi , Nishio Yumi , Isobe Midori , Fukuda Minoru , Uenaka Akiko , Oka Mikio , Nakayama Eiichi
Published: April 2023

OS of the advanced lung adenocarcinoma patients with different EGFR mutation types.
Supplementary Tables 1 - 5 from Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer
Authors: Abdel-Fatah Tarek M. , Ball Graham , Lee Andrew H.S. , Pinder Sarah , MacMilan R. Douglas , Cornford Eleanor , Moseley Paul M. , Silverman Rafael , Price James , Latham Bruce , Palmer David , Chan Arlene , Ellis Ian O. , Chan Stephen Y.T.
Published: April 2023

Supplementary Tables 1 to 5. Table (S1): Clinico-pathological characteristics of all three individual cohorts and the sum of all three together. Table (S2): Summery of pathological features that have been reviewed Table (S3): Univariate and multivariate backward step-wise analysis for factors associated with disease free survival (DFS) in the training cohort. Table (S4): Summery of the code system that has been used for calculation of Nottingham clinico-pathological response index (NPRI) Table (S5): Univariate analysis for clinicopathological features associated with disease free survival (DFS) and breast cancer specific survival (BCSS) in the training, internal and external validation cohorts.
supplementary figure 2 from Preclinical Assessment of Efficacy of Radiation Dose Painting Based on Intratumoral FDG-PET Uptake
Authors: Trani Daniela , Yaromina Ala , Dubois Ludwig , Granzier Marlies , Peeters Sarah G.J.A. , Biemans Rianne , Nalbantov Georgi , Lieuwes Natasja , Reniers Brigitte , Troost Esther E.G.C. , Verhaegen Frank , Lambin Philippe
Published: April 2023

Experimental design. Hot Boost (Cold Boost ) 40% (60%) indicates 40% (60%) higher radiation dose to tumor sub-volume with the highest (lowest) FDG uptake than to the rest of the tumor.